How Much Hexarelin Per Day? (Daily Dose Guidelines)

Research from the University of Virginia School of Medicine found that single-dose hexarelin administration produces a 4–8× spike in growth hormone within 30 minutes. But the response diminishes by 60% when administered at the same dose twice daily without sufficient spacing. The peptide's receptor desensitisation profile means dosing frequency matters as much as total daily amount.

Our team has supported hundreds of research facilities in optimising hexarelin protocols. The gap between effective and ineffective dosing comes down to three variables most suppliers never explain: pulse timing, receptor recovery windows, and administration route.

How much hexarelin should be administered per day in research settings?

Standard research protocols use 200–300 mcg per day divided into 2–3 subcutaneous administrations spaced 4–6 hours apart. Each pulse stimulates growth hormone release peaking at 20–40 minutes post-injection, with receptor sensitivity fully recovering after approximately 3–4 hours. Single daily doses above 200 mcg show diminishing returns due to ghrelin receptor (GHSR-1a) downregulation within the first 90 minutes of exposure.

Most guides define hexarelin as a growth hormone secretagogue and stop there. That definition misses the mechanism driving optimal dosing: hexarelin binds to ghrelin receptors in the pituitary and hypothalamus with 10–15× the binding affinity of endogenous ghrelin. But those receptors desensitise rapidly under sustained or excessive exposure. A 400 mcg single dose doesn't produce twice the GH response of a 200 mcg dose; it produces receptor saturation followed by refractory period extension. This article covers the dose-response curve hexarelin follows, the timing architecture that prevents receptor desensitisation, and the preparation errors that render dosing calculations meaningless.

Understanding Hexarelin's Dose-Response Mechanism

Hexarelin operates through ghrelin receptor (GHSR-1a) activation. A G-protein coupled receptor expressed densely in the anterior pituitary somatotrophs and arcuate nucleus of the hypothalamus. When hexarelin binds to GHSR-1a, it triggers calcium influx and cAMP signalling cascades that stimulate somatotroph degranulation, releasing stored growth hormone into circulation within 15–30 minutes.

The critical variable researchers overlook: GHSR-1a demonstrates rapid homologous desensitisation. After initial agonist binding, beta-arrestin proteins translocate to the receptor within 60–90 seconds, uncoupling the receptor from its G-protein signalling complex and initiating internalisation via clathrin-coated pits. Full receptor resensitisation. The process of receptor recycling back to the cell surface. Takes approximately 3–4 hours under standard conditions. This is why studies using continuous hexarelin infusion show peak GH response in the first 30 minutes followed by progressive attenuation despite ongoing peptide exposure.

Dose-response data from published protocols shows a ceiling effect: 100 mcg subcutaneous hexarelin produces approximately 60% of maximal GH stimulation, 200 mcg produces 85–95%, and doses above 300 mcg show minimal additional response. Our experience working with research labs confirms this pattern. Protocols attempting 500+ mcg single doses report no additional benefit and frequently observe prolonged refractory periods extending receptor recovery to 6+ hours.

Standard Daily Dosing Protocols in Research Settings

Most hexarelin research protocols follow one of three timing architectures, each designed around receptor recovery kinetics:

Twice-daily protocol (200–300 mcg total): 100–150 mcg administered subcutaneously upon waking (fasted state), second dose 100–150 mcg administered 6–8 hours later (ideally pre-exercise or fasted). This pattern maintains receptor sensitivity by spacing administrations beyond the 3–4 hour recovery window while capitalising on natural GH pulse timing. Early morning and late afternoon.

Three-times-daily protocol (300–450 mcg total): 100 mcg doses administered at 4–6 hour intervals throughout the day. Studies published in the Journal of Clinical Endocrinology & Metabolism using this pattern showed sustained GH elevation without tachyphylaxis over 4-week observation periods. The narrower spacing works because each individual pulse remains below the receptor saturation threshold.

Pulse protocol (200 mcg single dose): Single administration 30–60 minutes pre-exercise or before sleep. This approach maximises peak GH response during periods of metabolic demand or natural somatotroph activity (nocturnal GH pulse). Our team has found this pattern most effective in short-term studies (≤14 days) where receptor preservation isn't the primary concern.

Administration route significantly affects required dosing: subcutaneous injection delivers 85–95% bioavailability with peak plasma concentration at 15–25 minutes, while oral administration shows <5% bioavailability due to peptide bond degradation by gastric proteases. Intranasal formulations achieve approximately 30–40% bioavailability but require 3–4× the subcutaneous dose to produce equivalent GH response.

Reconstitution and Dose Calculation Precision

Hexarelin is supplied as lyophilised powder in 2 mg or 5 mg vials. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) follows standard peptide protocols: inject 2 mL bacteriostatic water into a 2 mg vial for a final concentration of 1000 mcg/mL (1 mcg per microliter). At this concentration, a 200 mcg dose equals 0.2 mL (20 units on a U-100 insulin syringe).

The most common dosing error we've observed: researchers reconstitute with incorrect water volume and calculate doses based on the vial's stated total content rather than actual concentration. A 5 mg vial reconstituted with 1 mL yields 5000 mcg/mL. But if the researcher assumes '1 mL = one dose', they're administering 25× the intended amount. High-purity Hexarelin from verified suppliers includes detailed reconstitution instructions, but calculation verification remains the researcher's responsibility.

Storage post-reconstitution: refrigerate at 2–8°C and use within 30 days. Lyophilised powder stored at −20°C maintains potency for 24+ months. Temperature excursions above 25°C for more than 48 hours cause irreversible peptide degradation. Hexarelin's molecular structure (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) contains temperature-sensitive peptide bonds that denature when exposed to heat.

Hexarelin Per Day Daily Dose: Research Protocol Comparison

| Protocol Type | Total Daily Dose | Administration Frequency | Timing Pattern | Receptor Desensitisation Risk | Typical Study Duration | Professional Assessment |
|—|—|—|—|—|—|
| Standard Twice-Daily | 200–300 mcg | 2× daily | Morning (fasted) + Evening (pre-exercise or fasted) | Low. 6–8 hour spacing allows full receptor recovery | 4–12 weeks | Optimal balance between sustained GH elevation and receptor preservation. Best for long-term research |
| Intensive Three-Pulse | 300–450 mcg | 3× daily | Every 4–6 hours throughout waking period | Moderate. Shorter intervals risk cumulative desensitisation if dosing exceeds 100 mcg per pulse | 2–6 weeks | Higher total GH exposure but requires strict timing discipline. Suitable for short-term metabolic studies |
| Single High-Dose Pulse | 200–300 mcg | 1× daily | Pre-exercise or pre-sleep | Moderate-High. Single large dose saturates receptors, extending refractory period to 6+ hours | ≤14 days | Maximum acute GH spike but poorest receptor preservation. Use only in acute-phase studies |
| Conservative Research Dose | 100–200 mcg | 1–2× daily | Flexible timing with ≥6 hour spacing | Very Low. Conservative dosing maintains receptor sensitivity indefinitely | 12+ weeks | Preferred for baseline establishment or long-observation studies where consistency matters more than peak response |

Key Takeaways

• Hexarelin dosing ranges from 200–300 mcg per day split into 2–3 administrations for optimal receptor preservation and sustained GH elevation.
• Each hexarelin pulse stimulates a 4–8× growth hormone spike within 30 minutes, but receptor desensitisation occurs within 90 minutes and requires 3–4 hours for full recovery.
• Single doses above 300 mcg produce minimal additional GH response due to GHSR-1a receptor saturation. Higher doses extend refractory periods without increasing efficacy.
• Subcutaneous administration delivers 85–95% bioavailability; oral routes show <5% due to gastric peptide degradation.
• Standard reconstitution: 2 mL bacteriostatic water per 2 mg vial yields 1000 mcg/mL concentration. A 200 mcg dose equals 0.2 mL (20 units on U-100 syringe).
• Spacing doses 6–8 hours apart prevents cumulative receptor desensitisation observed in continuous-exposure protocols.

What If: Hexarelin Dosing Scenarios

What If the Research Protocol Calls for Higher Daily Doses (400+ mcg)?

Split the total into 3–4 smaller pulses rather than increasing individual dose size. A 400 mcg daily protocol performs better as four 100 mcg doses spaced 4 hours apart than two 200 mcg doses. The smaller pulses stay below receptor saturation threshold while maintaining elevated GH throughout the observation period. Studies attempting 300+ mcg single doses consistently report diminished response by day 7–10 as receptor downregulation accumulates.

What If GH Response Diminishes After 2–3 Weeks on Protocol?

This indicates receptor desensitisation outpacing recovery. The standard intervention: reduce dosing frequency to once daily for 5–7 days while maintaining individual pulse size, allowing receptor populations to fully resensitise. Research from the European Journal of Endocrinology demonstrated that a 7-day washout period restored full GH responsiveness in subjects showing tachyphylaxis after 21 days of twice-daily hexarelin. Alternatively, some protocols cycle hexarelin 5 days on / 2 days off to prevent cumulative desensitisation.

What If the Lyophilised Powder Was Stored at Room Temperature Before Reconstitution?

Lyophilised hexarelin tolerates room temperature (20–25°C) for up to 30 days without significant potency loss. The critical temperature threshold is 30°C. Sustained exposure above this point accelerates peptide bond hydrolysis. If powder was stored above 30°C for more than 72 hours, potency testing via HPLC is recommended before use. We've seen researchers waste entire studies using heat-degraded peptides that showed normal appearance but zero biological activity.

What If Subcutaneous Injection Isn't Feasible in the Research Model?

Intranasal formulations exist but require 3–4× the subcutaneous dose to achieve equivalent plasma GH levels due to lower bioavailability (30–40% vs 85–95%). A protocol using 200 mcg subcutaneous would translate to approximately 600–800 mcg intranasal. The alternative is intramuscular injection, which delivers similar bioavailability to subcutaneous but with slightly faster absorption kinetics (peak at 10–15 minutes vs 20–25 minutes).

The Blunt Truth About Hexarelin Dosing Claims

Here's the honest answer: most online hexarelin dosing recommendations are copied from bodybuilding forums, not published research. The '200 mcg twice daily' protocol became standard because it appeared in a 1990s Italian study on GH-deficient patients. Not because it's universally optimal for all research applications.

The evidence is clear: optimal hexarelin dosing depends entirely on study objectives. Short-term acute GH stimulation studies benefit from higher single doses (200–300 mcg once daily). Long-term metabolic or body composition research requires lower per-pulse doses (100–150 mcg) with maintained frequency to prevent receptor desensitisation. Protocols blindly following 'standard' dosing without accounting for receptor kinetics consistently underperform in our experience.

Another truth most suppliers won't state: hexarelin loses effectiveness faster than other growth hormone secretagogues. GHRP-2 and GHRP-6 show slower receptor desensitisation curves, making them better choices for studies extending beyond 8–12 weeks. Hexarelin's advantage is acute potency. The highest peak GH response per mcg administered. But that comes at the cost of faster tachyphylaxis development.

Timing Hexarelin Administration for Specific Research Outcomes

Hexarelin's GH-stimulating effect peaks 20–30 minutes post-administration and returns to baseline within 90–120 minutes. This kinetic profile makes timing critical for studies targeting specific metabolic windows.

Pre-exercise administration (30 minutes before activity) capitalises on the synergistic effect between exogenous GH pulse and exercise-induced growth hormone release. Studies in the Journal of Applied Physiology found that hexarelin administered 30 minutes pre-resistance training produced 40% higher peak GH levels compared to resting administration, likely due to exercise-induced reduction in somatostatin tone. The inhibitory signal that normally suppresses GH release.

Pre-sleep administration aligns hexarelin's GH pulse with the body's natural nocturnal somatotroph surge, which occurs 60–90 minutes after sleep onset. Research protocols using this timing report improved sleep architecture markers (increased slow-wave sleep percentage) alongside elevated overnight GH exposure. The mechanism: hexarelin's ghrelin receptor activation influences orexin and GABA pathways involved in sleep regulation.

Fasted-state administration produces the most consistent GH response because elevated blood glucose and insulin suppress growth hormone release through direct somatostatin stimulation. Protocols requiring standardised baseline conditions administer hexarelin after an overnight fast or ≥4 hours post-meal to minimise metabolic interference.

For researchers comparing hexarelin to other growth hormone research tools, our full peptide collection includes mechanistically complementary compounds like GHRP-2 and MK-677, each with distinct receptor profiles and desensitisation kinetics suited to different study designs.

Hexarelin's value in peptide research lies in its unmatched acute GH-stimulating potency. But that potency demands dosing precision most guides ignore. The difference between a successful hexarelin study and a failed one isn't the peptide's quality. It's whether the protocol accounts for receptor desensitisation, administration timing, and preparation accuracy from day one.